"The physicians and staff who are part of the Translational Oncology Program at US Oncology are a very special team," said Dr. Von Hoff. "It takes a special kind of dedication and attention to detail to perform a trial with a new outsourced agent. Treating and trying to help more than 1,000 patients through a Phase I trial is a milestone for the hard work of members of our TOP team. The most important thing is that our patients have had a chance to receive targeted cancer therapy as early as possible, so they have the best chance to be helped."
Phase I trials are the beginning of clinical trial work – testing ideas and theories that could go on to save lives or improve the quality of life for patients. These innovative trials often include the capability to examine pharmacokinetic aspects of the investigational agent as well as the pharmacogenetic variations among different patient populations to predict response. These elements of a Phase I trial help investigators understand how a drug is absorbed, distributed, metabolized and eliminated in the body so that toxicity can be closely monitored. This information is used to help bring the trial into Phase II, the next step in proving a new therapy's value in cancer care.
"Researchers affiliated with US Oncology TOP have investigator experience ranging from six years to more than 33 years," says Steve Jones, MD, medical director of US Oncology Research and a medical oncologist with Texas Oncology, an affiliate of the United Network of US Oncology. "Our average TOP investigator has 18 years of clinical research experience. We're proud of our record at US Oncology Research of having played a role in the development of 42 drugs approved by the FDA. With the work of [Dr.] Dan Von Hoff and the other TOP physicians across the country, we are bringing innovative treatments to patients early on to give them the best chance of survival and providing the industry with information that advances canc
|SOURCE US Oncology, Inc.|
Copyright©2010 PR Newswire.
All rights reserved